Anatara Lifesciences Limited engages in the research and development of evidence based solutions for gastrointestinal diseases in animals and humans in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.14|
|52 Week High||AU$0.14|
|52 Week Low||AU$0.28|
|1 Month Change||-3.33%|
|3 Month Change||-3.33%|
|1 Year Change||-14.71%|
|3 Year Change||-68.13%|
|5 Year Change||-89.02%|
|Change since IPO||-65.48%|
Recent News & Updates
|ANR||AU Biotechs||AU Market|
Return vs Industry: ANR underperformed the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: ANR underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: ANR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ANR's weekly volatility (8%) has been stable over the past year.
About the Company
Anatara Lifesciences Limited engages in the research and development of evidence based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming (GaRP), a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD); and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets.
Anatara Lifesciences Fundamentals Summary
|ANR fundamental statistics|
Is ANR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANR income statement (TTM)|
|Cost of Revenue||AU$840.82k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.028|
|Net Profit Margin||0.00%|
How did ANR perform over the long term?See historical performance and comparison
Is Anatara Lifesciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ANR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ANR is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: ANR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANR is good value based on its PB Ratio (2.7x) compared to the AU Biotechs industry average (4.9x).
How is Anatara Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anatara Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Anatara Lifesciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANR is currently unprofitable.
Growing Profit Margin: ANR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANR is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare ANR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: ANR has a negative Return on Equity (-52.11%), as it is currently unprofitable.
How is Anatara Lifesciences's financial position?
Financial Position Analysis
Short Term Liabilities: ANR's short term assets (A$4.2M) exceed its short term liabilities (A$402.6K).
Long Term Liabilities: ANR's short term assets (A$4.2M) exceed its long term liabilities (A$94.1K).
Debt to Equity History and Analysis
Debt Level: ANR is debt free.
Reducing Debt: ANR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANR has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 9.1% each year.
What is Anatara Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as the Chief Executive Officer of Anatara Lifesciences Limited since December 2, 2018. Mr. Lydeamore served as the Chief Financial Officer...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD351.50K) is about average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: ANR's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: ANR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.
Anatara Lifesciences Limited's employee growth, exchange listings and data sources
- Name: Anatara Lifesciences Limited
- Ticker: ANR
- Exchange: ASX
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$10.298m
- Shares outstanding: 71.02m
- Website: https://www.anataralifesciences.com
- Anatara Lifesciences Limited
- 62 Lygon Street
- Level 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:01|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.